OTCMKTS:PIRS

Delisted

Pieris Pharmaceuticals Stock News

Healthcare > Biotechnology

Buy PIRS

*Your capital is at risk

$13.60

+0 (+0%)

At Close: Mar 12, 2025

Top Penny Stocks to Watch After the Long Weekend

11:45am, Sunday, 05'th Sep 2021

Are these penny stocks on your watchlist this week? The post Top Penny Stocks to Watch After the Long Weekend appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Penny Stocks To Watch For September With Upcoming Events

02:15pm, Monday, 30'th Aug 2021

These penny stocks could be in focus as we turn the page on a new month. The post 5 Penny Stocks To Watch For September With Upcoming Events appeared first on Penny Stocks to Buy, Picks, News and Info

Which Biotech Stock Will Shock the Market in 2022?

10:40am, Friday, 27'th Aug 2021

Over the last few years, three tiny biotechs emerged out of nowhere to give amazing returns to early investors. Which biotech might pull off a similar feat in 2022?

Pieris Pharmaceuticals Announces PRS-220 Presentation at ERS Highlighting Preclinical Data for CTGF Inhibitor

09:00am, Tuesday, 24'th Aug 2021

BOSTON, MA / ACCESSWIRE / August 24, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® tech

Pieris Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update

07:00am, Wednesday, 04'th Aug 2021

COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON WEDNESDAY, AUGUST 4, 2021 AT 8:00 AM EDT Announced inhaled program PRS-220 for the treatment of IPF and was selected to receive a Bavarian government gra

Pieris Pharmaceuticals Strengthens Executive R&D Leadership Team

08:00am, Tuesday, 03'rd Aug 2021

Tim Demuth, M.D., Ph.D., joins Pieris as Chief Medical Officer Shane Olwill, Ph.D.

Pieris Pharmaceuticals to Host Second Quarter 2021 Investor Call and Provide Corporate Update on August 4, 2021

08:00am, Wednesday, 28'th Jul 2021

BOSTON, MA / ACCESSWIRE / July 28, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technol

Are These 8 Penny Stocks to Watch on Your List Right Now?

05:03pm, Wednesday, 30'th Jun 2021

Making a penny stocks watchlist for 2021? Check these 8 out The post Are These 8 Penny Stocks to Watch on Your List Right Now?

This Risky Micro-Cap Could Pay Off Big

08:31am, Wednesday, 30'th Jun 2021

Pieris Pharmaceuticals is introducing a whole new class of drugs to the marketplace.

Pieris Stock Moves Higher On €14.2M Grant For PRS-220 In Post-COVID Pulmonary Fibrosis

09:18am, Friday, 25'th Jun 2021

Pieris Pharmaceuticals Inc (NASDAQ: PIRS) has announced the development of PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor to treat idiopathic pulmonary fibrosis

Pieris Pharmaceuticals Announces Inhaled CTGF Inhibitor PRS-220 for Idiopathic Pulmonary Fibrosis and 17 Million Dollar Grant From Bavarian Government To Accelerate Program Development for Post-COVID-19 Pulmonary Fibrosis

07:00am, Friday, 25'th Jun 2021

PRS-220, an oral inhaled Anticalin protein targeting CTGF, a fully proprietary drug candidate for respiratory disease, is being developed as a local treatment for idiopathic pulmonary fibrosis Grant t

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by